Belzutifan plus cabozantinib combination shows promise in advanced kidney cancer
Updated results from the phase 2 LITESPARK-003 trial with belzutifan [...]
Promising new combination therapy for advanced kidney cancer
Combinations of tyrosine kinase inhibitors plus immunotherapy have improved treatment [...]
Promising new immunotherapy combination for advanced kidney cancer
The first results from a phase 2 study (FRACTION-RCC) looking [...]
New treatment for pretreated advanced kidney cancer shows promise
A new treatment, called NDI-101150 has been shown to be [...]
Intermittent immunotherapy in patients with metastatic kidney cancer
The combination of ipilimumab/nivolumab is approved for patients as a [...]
ASCO 2024: Treatment-free survival with cabozantinib plus nivolumab
At the American Society of Clinical Oncology Annual Meeting (ASCO) last [...]
Stereotactic radiotherapy plus immunotherapy for brain metastases
Stereotactic radiosurgery (SRS) is a procedure that uses special equipment [...]
Treatment options in first-line metastatic kidney cancer
Over the past 10 years or so, the use of [...]
Comparison of cabozantinib with axitinib as second-line treatment for metastatic kidney cancer
To date, there have not been any studies that have [...]
Lenvatinib plus everolimus for patients with metastatic kidney cancer
The treatment of heavily pretreated patients with metastatic kidney cancer [...]
